FrancophonIA/ELRC3.0 huggingface dataset:
English: Intrarosa must not be used in patients with the following conditions: genital bleeding where the cause has not been diagnosed, known or suspected breast cancer or oestrogen-dependent cancer, previous breast cancer, untreated endometrial hyperplasia (thickening of the lining of the womb), acute (shortterm) liver disease, previous liver disease where liver function tests are still abnormal, previous or current venous thromboembolism (formation of blood clots in the veins), thrombophilic disorders (abnormal blood clotting), active or recent arterial thromboembolic disease (disease caused by blood clots in the arteries), porphyria (inability to break down chemicals called porphyrins).
Estonian: Intrarosat ei tohi kasutada järgmiste haigusseisunditega patsientidel: diagnoosimata genitaalverejooksud, teadaolev või kahtlustatav rinnavähk või östrogeensõltuv vähk, varasem rinnavähk, endomeetriumi hüperplaasia (emaka limaskesta paksenemine), mis on jäänud ravimata, äge (lühiajaline) maksahaigus, varasem maksahaigus, kui maksafunktsiooni testide tulemused ei ole normaliseerunud, varasem või praegune venoosne trombemboolia (verehüübed veenides), trombofiilsed häired (ebanormaalne verehüübimine), aktiivne või hiljutine arteriaalne trombemboolia (haigus, mida põhjustavad verehüübed arterites), porfüüria (suutmatus lagundada keemilisi aineid porfüriine).
English: What is Intrarosa and what is it used for?
Estonian: Mis on Intrarosa ja milleks seda kasutatakse?
English: Why is Intrarosa approved?
Estonian: Miks Intrarosa heaks kiideti?
English: The company that markets Intrarosa is required to conduct a study on how the medicine is used in clinical practice, including whether it is used according to the authorised product information.
Estonian: Intrarosa turustaja peab korraldama uuringu ravimi kasutamise kohta kliinilises praktikas, uurides sealhulgas, kas seda kasutatakse kooskõlas heakskiidetud ravimiteabega.
English: Intrarosa contains the active substance prasterone, also known as dehydroepiandrosterone (DHEA).
Estonian: Intrarosa sisaldab toimeainena prasterooni, mida nimetatakse ka dehüdroepiandrosterooniks (DHEA).
English: Pain during sexual intercourse was self-assessed by patients using a standard scale ranging from 0 (no pain) to 3 (severe pain).
Estonian: Vahekorraaegset valu hindasid patsiendid ise standardsel hindamisskaalal 0st (valu puudub) 3-ni (tugev valu).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Intrarosa have also been included in the summary of product characteristics and the package leaflet.
Estonian: Intrarosa ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This is a summary of the European public assessment report (EPAR) for Intrarosa.
Estonian: See on ravimi Intrarosa Euroopa avaliku hindamisaruande kokkuvõte.
English: What are the risks associated with Intrarosa?
Estonian: Mis riskid Intrarosaga kaasnevad?
English: It is not intended to provide practical advice on how to use Intrarosa.
Estonian: Hindamisaruandes ei anta Intrarosa kasutamise praktilisi nõuandeid.
English: The pain reduced by 1.3 and 1.4 points with Intrarosa compared with 0.9 and 1.1 points with placebo.
Estonian: Intrarosaga vähenes valu 1,3 ja 1,4 punkti ning platseeboga 0,9 ja 1,1 punkti võrra.
English: The most common side effect with Intrarosa (which may affect up to 1 in 10 people) is vaginal discharge.
Estonian: Intrarosa kõige sagedam kõrvalnäht (võib esineda kuni 1 patsiendil 10st) on tupevoolus.
English: Intrarosa is available as a 6.5 mg pessary.
Estonian: Intrarosat turustatakse 6,5 mg vaginaalsuposiidina.
English: Patients taking Intrarosa had a modest reduction in pain during sexual intercourse, which was similar or better to the effect seen in patients taking placebo.
Estonian: Intrarosat kasutanud patsientidel vähenes vahekorraaegne valu mõõdukal määral ning võrreldes platseeboga oli toime sarnane või parem.
English: Two studies involving 813 post-menopausal women with vulvar and vaginal atrophy found that treatment with Intrarosa was more effective than placebo (a dummy treatment) at reducing signs of thinning (atrophy) of vaginal tissues.
Estonian: Kahes uuringus, milles osales 813 häbemeatroofia ja atroofilise tupepõletikuga menopausijärgset naist, oli Intrarosa-ravi tupe limaskesta õhenemise (atroofia) sümptomite vähendamisel efektiivsem kui platseebo (näiv ravim).
English: In women with vulvar and vaginal atrophy, the wall of the vagina and surrounding tissues become thinner and can cause symptoms such as dryness, irritation and soreness around the genital area, and painful sexual intercourse.
Estonian: Häbemeatroofia ja atroofilise tupepõletikuga naistel on tupesein ja ümbritsevad koed õhenenud, mis võib põhjustada selliseid sümptomeid nagu genitaalpiirkonna kuivus, ärritus ja valulikkus ning valu vahekorra ajal.
English: How is Intrarosa used?
Estonian: Kuidas Intrarosat kasutatakse?
English: For more information about treatment with Intrarosa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Intrarosaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What benefits of Intrarosa have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Intrarosa kasulikkus?
English: For practical information about using Intrarosa, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Intrarosa kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: There was also a decrease in the number of parabasal cells (which normally increase with atrophy) of 42% and 47% with Intrarosa compared with 2% and 12% with placebo.
Estonian: Samuti täheldati parabasaalsete rakkude arvu (mis atroofia korral enamasti suureneb) vähenemist - Intrarosaga vähenes see 42% ja 47% ning platseeboga 2% ja 12% võrra.
English: For the full list of side effects reported with Intrarosa, see the package leaflet.
Estonian: Intrarosa kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Women should insert the pessary into their vagina, once daily, at bedtime.
Estonian: Vaginaalsuposiit tuleb tuppe sisestada üks kord ööpäevas enne magamaminekut.
English: Results showed that the number of superficial cells (which normally falls with atrophy) increased by 6% and 10% with Intrarosa compared with about 1% and 2% with placebo.
Estonian: Tulemustest nähtus, et pindmiste rakkude arv (mis atroofia korral enamasti väheneb) suurenes Intrarosaga 6% ja 10% ning platseeboga 1% ja 2% võrra.
English: Intrarosa is a medicine used to treat postmenopausal women with moderate to severe symptoms of vulvar and vaginal atrophy.
Estonian: Intrarosa on ravim, mida kasutatakse mõõdukate kuni raskete häbemeatroofia ja atroofilise tupepõletiku sümptomitega menopausijärgsete naiste raviks.
English: In addition, Intrarosa treatment was better at increasing acidity in the vagina (which normally becomes less acidic with atrophy), with pH values reducing by 0.9 and 1.0 with Intrarosa and by 0.2 and 0.3 with placebo.
Estonian: Peale selle vähendas Intrarosa-ravi paremini tupe happesust (atroofia korral see enamasti suureneb)Intrarosaga vähenesid pH-väärtused 0,9 ja 1,0 ühiku ning platseeboga 0,2 ja 0,3 ühiku võrra.
English: As a result of increasing oestrogen levels, the number of superficial cells in the tissues in and around the vagina increases thus relieving the symptoms of vaginal atrophy.
Estonian: Östrogeenisisalduse suurenemise toimel tekib tupe limaskestas ja ümbritsevates kudedes rohkem pindmisi rakke, aidates leevendada atroofilise tupepõletiku sümptomeid.
English: The effect seen in the placebo group was explained by the lubricant effect of the excipient.
Estonian: Platseeborühmas täheldatud toimet võis selgitada sellega, et platseebo sisaldas libestava toimega abiainet.
English: The active substance of Intrarosa, prasterone, is converted into the sex hormones oestrogens and androgens when inserted into the vagina.
Estonian: Intrarosa toimeaine prasteroon muutub tuppe sisestatuna östrogeenideks ja androgeenideks (suguhormoonid).
English: Intrarosa has been shown to improve the structure of the vaginal tissues and to have a modest effect on pain during sexual intercourse.
Estonian: Tõendite põhjal parandab Intrarosa tupe limaskesta struktuuri ja leevendab mõõdukalt valu vahekorra ajal.
English: How does Intrarosa work?
Estonian: Kuidas Intrarosa toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Intrarosa on retseptiravim.
English: In women who have been through the menopause, the thinning of the tissues in and around the vagina is caused by a fall in levels of the sex hormone oestrogen.
Estonian: Menopausijärgsetel naistel tekib organismis vähem östrogeeni (naissuguhormoon) ning tupe limaskest ja ümbritsevad koed seetõttu õhenevad.
English: This did not affect long-term development of colonies.
Estonian: See ei mõjutanud mesilasperede pikaajalist arengut.
English: Dead mites were counted daily in the first study and three times per week in the second study for three weeks post treatment.
Estonian: Esimeses uuringus loendati surnud lestad kord päevas ja teises uuringus kolm korda nädalas kolme nädala jooksul pärast ravi.
English: The full EPAR for Oxybee can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Oxybee kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The dispersion should be warmed to 30-35˚C before application.
Estonian: Enne kasutamist tuleb dispersioon soojendada temperatuurile 30-35 ˚C.
English: The effectiveness of Oxybee to kill mites was 97% and 95% in these studies.
Estonian: Nendes uuringutes hävitas Oxybee vastavalt 97% ja 95% lestadest.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Oxybee's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Oxybee kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: People must not eat, drink or smoke while using the medicine.
Estonian: Ravimit kasutav isik ei tohi selle käsitsemise ajal süüa, juua ega suitsetada.
English: Used measuring devices and empty containers should be disposed of immediately in a safe way.
Estonian: Kasutatud mõõtevahendid ja tühjad mahutid peab ohutul viisil otsekohe kõrvaldama.
English: Hands and exposed skin should be washed with soap and plenty of water immediately.
Estonian: Käed ja saastunud nahk tuleb viivitamata pesta seebi ja rohke veega.
English: In case of eye contact, the affected eye should be rinsed thoroughly with water (contact lenses should be removed first).
Estonian: Ravimi sattumisel silma tuleb silma hoolikalt veega pesta (enne seda eemaldada kontaktläätsed).
English: Oxybee is trickled onto bees in the hive and should only be used when the temperature outside the hives is at least 3˚C.
Estonian: Oxybee niristatakse mesitarus olevatele mesilastele ning seda tohib kasutada üksnes juhul, kui tarust väljaspool on temperatuur vähemalt 3 ˚C.
English: Other information about Oxybee
Estonian: Muu teave Oxybee kohta
English: The most common side effect with Oxybee (which may affect more than 1 in 10 bee colonies) is an increased number of bee deaths.
Estonian: Oxybee kõige sagedam kõrvaltoime (võib esineda enam kui 1 mesilasperel 10st) on mesilaste suremuse suurenemine.
English: Contaminated clothing should be removed immediately.
Estonian: Saastunud kaitseriietus tuleb viivitamata seljast võtta.
English: The effectiveness of Oxybee against varroa mites was investigated in two field studies in European countries with different climates.
Estonian: Oxybee efektiivsust varroalestade hävitamisel uuriti kahes erinevate kliimatingimustega Euroopa riikides korraldatud väliuuringus.
English: It is not intended to provide practical advice on how to use Oxybee.
Estonian: Hindamisaruandes ei anta Oxybee kasutamise praktilisi nõuandeid.
English: Oxybee is highly acidic and could be irritating or corrosive to the skin, eyes and mucous membranes (inner lining of body cavities like the mouth or nose).
Estonian: Oxybee on tugevalt happeline ning võib nahka, silmi ja limaskesti (kehaavade, nt suu või nina sisekihti) ärritada või söövitada.
English: What is Oxybee and what is it used for?
Estonian: Mis on Oxybee ja milleks seda kasutatakse?
English: If the product is accidentally swallowed by a person, their mouth should be cleaned with water and water or milk should be drunk, but vomiting should not be induced.
Estonian: Ravimi juhuslikul allaneelamisel tuleb kannatanu suu pesta veega ja lasta tal juua vett või piima, kuid mitte esile kutsuda oksendamist.
English: This is a summary of the European public assessment report (EPAR) for Oxybee.
Estonian: See on ravimi Oxybee Euroopa avaliku hindamisaruande kokkuvõte.
English: The varroa mite feeds on the haemolymph (blood) of adult bees and on brood (developing stages of the honey bee) resulting in harm and/or death of bees; the mite can also help spread viruses and bacteria.
Estonian: Varroalest toitub täiskasvanud mesilaste hemolümfist (verest) ja haudmest (mesilaste valmikueelsed arengujärgud), põhjustades mesilastele kahjustusi ja/või mesilaste surma; samuti võib varroalest levitada viirusi ja baktereid.
English: In the first study treatment with Oxybee was compared to another oxalic acid medicine and to a group with no treatment whilst in the second study treatment with Oxybee was compared to a group with no treatment.
Estonian: Esimeses uuringus võrreldi Oxybee ravi teise oksaalhapet sisaldava ravimi kasutamisega ning ravi puudumisega (kontrollrühm); teises uuringus võrreldi ravi Oxybeega ravi puudumisega.
English: A significant mite infestation can lead to the collapse of a honey bee colony.
Estonian: Ulatuslik lestainfestatsioon võib põhjustada mesilaspere hävimise.
English: How oxalic acid works on mites is not well understood but is thought to be due to the acidity of the medicine, which kills the mites on contact.
Estonian: Oksaalhappe toimemehhanism lestade korral ei ole täielikult teada, kuid arvatavalt on see seotud ravimi happesusega, mille tõttu lestad ravimiga kokku puutudes hävivad.
English: Medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Seejärel tuleb pöörduda kohe arsti poole ja näidata talle pakendi infolehte või etiketti.
English: The withdrawal period for honey from honey bees treated with Oxybee is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Oxybeega ravitud mesilaste mee keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: For practical information about using Oxybee, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Oxybee kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: Why is Oxybee approved?
Estonian: Miks Oxybee heaks kiideti?
English: Protective clothing, acid resistant gloves and safety glasses should be worn during treatment.
Estonian: Ravimi käsitsemisel tuleb kanda kaitseriietust, happekindlaid kindaid ja kaitseprille.
English: Oxybee contains the active substance oxalic acid.
Estonian: Oxybee sisaldab toimeainena oksaalhapet.
English: What are the risks associated with Oxybee?
Estonian: Mis riskid Oxybeega kaasnevad?
English: Varroosis is a disease of honey bees caused by infestation with a parasite called varroa mite (Varroa destructor).
Estonian: Varroos on meemesilaste haigus, mida põhjustab varroalesta (parasiitlest Varroa destructor) infestatsioon.
English: Oxybee is a medicine used to treat varroosis in honey bee colonies.
Estonian: Oxybee on ravim, mida kasutatakse varroosi raviks mesilasperedes.
English: The European Commission granted a marketing authorisation valid throughout the EU for Oxybee on 1 February 2018.
Estonian: Euroopa Komisjon andis Oxybeele müügiloa, mis kehtib kogu Euroopa Liidu territooriumil,
English: The withdrawal period is the time required after administration of a medicine before honey may be used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi mett inimtoiduks tarvitada.
English: Oxybee oxalic acid
Estonian: Oxybee oksaalhape
English: How does Oxybee work?
Estonian: Kuidas Oxybee toimib?
English: How is Oxybee used?
Estonian: Kuidas Oxybeed kasutatakse?
English: Oxybee is available as a powder and solution to prepare a bee-hive dispersion (a liquid for use inside the bee hive) and can be obtained without a prescription.
Estonian: Oxybeed turustatakse pulbri ja lahusena mesitaru dispersiooni valmistamiseks (vedelik mesitarus kasutamiseks) ning see on käsimüügiravim.
English: What benefits of Oxybee have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Oxybee kasulikkus?
English: Contact with these areas should be avoided, both directly and by hand-to-mouth or hand-to-eye contact.
Estonian: Vältida tuleb ravimi sattumist otse nahale, silmadesse või limaskestadele või käelt suhu ja käelt silma.
English: Oxybee can only be used on colonies without brood.
Estonian: Oxybeed tohib kasutada üksnes haudeta mesilasperedes.
English: These studies however, are of limited relevance.
Estonian: Need uuringud on aga piiratud tähtsusega.
English: ATC code: A16AB12.
Estonian: ATC-kood: A16AB12.
English: It is important to initiate treatment as early as possible.
Estonian: Oluline on ravi võimalikult varajane alustamine.
English: It is not known whether elderly patients respond differently from younger patients.
Estonian: Ei ole teada, kas eakad patsiendid reageerivad ravile noorematest patsientidest erinevalt.
English: Difference in changes
Estonian: Muutuste erinevus
English: Elderly patients (≥ 65 years old)
Estonian: Erirühmad Eakad patsiendid (≥ 65 aasta vanused)
English: No differences in the safety profile were observed.
Estonian: Erinevusi ohutusprofiilis ei täheldatud.
English: Date of first authorisation: 28 April 2014 Date of last renewal:
Estonian: Müügiloa esmase väljastamise kuupäev: 28 aprill 2014 Müügiloa viimase uuendamise kuupäev:
English: Currently available data are described in section 4.8 and section 5.1.
Estonian: Antud hetkel teadaolevad andmed on esitatud lõikudes 4.8 ja 5.1.
English: These problems can be a part of the disease and may be caused by pressure on your spinal cord.
Estonian: Need probleemid võivad olla osa haigusest ja nende põhjuseks võib olla surve seljaajule.
English: Treatment with Vimizim may be started at as young as an age possible and is intended for long term use.
Estonian: Ravi Vimizimiga võib alustada võimalikult varajases nooruses ja ravim on mõeldud pikaajaliseks kasutamiseks.
English: The educational pack should contain the following:
Estonian: Teabepakett peab sisaldama järgnevat:
English: Safety and pharmacodynamic results in these patients are consistent with results observed in the first 52 weeks (see section 4.8).
Estonian: Ohutuse ja farmakodünaamikaga seotud tulemused neil patsientidel olid kooskõlas esimese 52 nädala jooksul täheldatud tulemustega (vt lõik 4.8).
English: Other medicines and Vimizim Please tell your doctor if you are taking, have recently taken or might take any other medicines.
Estonian: Muud ravimid ja Vimizim Teatage oma arstile, kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: As a result, these substances do not get broken down and processed by the body as they should.
Estonian: Seetõttu ei lagunda ega töötle organism neid aineid nii, nagu peaks.
English: • Educational material for Healthcare Professionals
Estonian: • tervishoiuspetsialistidele mõeldud teabematerjalid.
English: Vimizim vs. placebo
Estonian: Vimizim vs. platseebo
English: Patients continued a long-term follow-up observational study for at least another 52 weeks, for a total of 104 weeks.
Estonian: Seejärel toimus patsientide pikaajaline veel vähemalt 52 nädalat kestev jälgimisuuring, kokku 104 nädalat.
English: CL, ml/minute/kg‡ t1/2, minute§
Estonian: CL, ml minutis 1 kg kohta‡ t1/2, minutites§
English: The total volume of the infusion should be delivered over approximately 4 hours (see Table 1).
Estonian: Kogu infusioonilahus tuleb manustada ligikaudu nelja tunni jooksul (vt tabel 1).
English: The safety and efficacy of Vimizim in patients older than 65 years has not been established, and no alternative treatment regimen can be recommended in these patients.
Estonian: Vimizimi ohutus ja efektiivsus patsientidel, kes on vanemad kui 65 aastat, ei ole tõestatud, ning neile ei ole võimalik anda alternatiivse ravikeemi soovitusi.
English: Each infusion will take approximately 4 hours.
Estonian: Iga infusioon kestab ligikaudu neli tundi.
English: Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from available data).
Estonian: Esinemissageduse määratlus on järgmine: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000) ja teadmata (ei saa hinnata olemasolevate andmete alusel).
English: - If you have an allergic reaction during your infusion your doctor may slow down, or stop your infusion.
Estonian: - Kui teil tekib infusiooni ajal allergiline reaktsioon, võib teie arst infundeerimist aeglustada või infusiooni katkestada.
English: Your doctor or nurse will give you some medicines before your treatment to reduce allergic reactions and you may also be given medicines to help control any fever.
Estonian: Arst või meditsiiniõde annab teile enne ravi allergiliste reaktsioonide vähendamiseks teatud ravimeid ja teile võidakse anda ka ravimeid, mis aitavad alandada palavikku.
English: Each vial of Vimizim is intended for single use only.
Estonian: Vimizimi iga viaal on mõeldud ainult ühekordseks kasutamiseks.
English: The evaluation of the peri- and postnatal development study in rats is hampered due to subsequent administration of DPH, and therefore of limited relevance.
Estonian: Rottidega tehtud peri- ja postnataalse arengu uuringu hindamist takistab DPH edasine manustamine ning seetõttu on vastavad uuringutulemused piiratud tähtsusega.
English: Do not use this medicine after the expiry date which is stated on the carton and vial after EXP.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja viaalil pärast tähist „EXP”.
English: Treatment has been shown to improve walking and to reduce the levels of keratan sulphate in the body.
Estonian: Tõestatud on, et ravi parandab kõndimist ja vähendab kerataansulfaadi sisaldust kehas.
English: Aseptic technique is to be used.
Estonian: Rakendada tuleb aseptilist tehnikat.
English: If you experience such a reaction, you should immediately contact your doctor.
Estonian: Kui teil tekib mõni selline reaktsioon, peate viivitamatult võtma ühendust oma arstiga.
English: Tell your doctor if you feel dizzy after your infusion, especially before driving or using any machine where dizziness might be dangerous.
Estonian: Teatage oma arstile, kui pärast infusiooni tunnete pearinglust, eeskätt enne autojuhtimist või mis tahes masinatega töötamist, mil pearinglusts võib olla ohtlik.
English: Warnings and precautions - If you are treated with Vimizim, you may develop infusion reactions.
Estonian: Hoiatused ja ettevaatusabinõud - Kui teid ravitakse Vimizimiga, võivad teil tekkida infusioonireaktsioonid.
English: AUC0-t, minute • µg/ml*
Estonian: AUC0-t, minutites • µg/ml*